You are using an unsupported browser.
Some features of this site may not function properly. For optimal user experience, please view this site in Chrome, Firefox, Safari, or Edge.


ZEJULA is a once-daily oral maintenance treatment for women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, after the cancer has completely or partially responded to the most recent chemotherapy.1

Thumbnail of a clip-board with a graph

ZEJULA Results

Look into the clinical trial data to learn about the effect of ZEJULA on women with recurrent ovarian cancer.

see the data

Thumbnail representing a woman

Is ZEJULA Right for You?

Find out if ZEJULA can help you with your recurrent ovarian, fallopian tube, or primary peritoneal cancer.

find out more

Thumbnail representing ZEJULA


Get details on ZEJULA dosing and handling, as well as information about how your doctor will monitor your treatment.

Information for you

Reference: 1. ZEJULA (niraparib) Prescribing Information. GlaxoSmithKline; 2021.

Back to Top